The active hormonal form of vitamin D, 1,25-dihydroxyvitamin D (1,25D) is an important modulator of the immune system, inhibiting cellular proliferation and regulating transcription of immune response genes. In order to characterize the genetic basis of variation in the immunomodulatory effects of 1,25D, we mapped quantitative traits of 1,25D response at both the cellular and the transcriptional level. We carried out a genome-wide association scan of percent inhibition of cell proliferation (I max ) induced by 1,25D treatment of peripheral blood mononuclear cells from 88 healthy African-American individuals. Two genome-wide significant variants were identified: rs1893662 in a gene desert on chromosome 18 (p = 2.32 x 10 −8 ) and rs6451692 on chromosome 5 (p = 2.55 x 10 −8 ), which may influence the anti-proliferative activity of 1,25D by regulating the expression of nearby genes such as the chemokine gene, CCL28, and the translation initiation gene, PAIP1. We also identified 8 expression quantitative trait loci at a FDR<0.10 for transcriptional response to 1,25D treatment, which include the transcriptional regulator ets variant 3-like (ETV3L) and EH-domain containing 4 (EHD4). In addition, we identified response eQTLs in vitamin D receptor binding sites near genes differentially expressed in response to 1,25D, such as FERM Domain Containing 6 (FRMD6), which plays a critical role in regulating both cell proliferation and apoptosis. Combining information from the GWAS of I max and the response eQTL mapping enabled identification of putative I max -associated candidate genes such as PAIP1 and the transcriptional repressor gene ZNF649. Overall, the variants identified in this study are strong candidates for immune traits and diseases linked to vitamin D, such as multiple sclerosis.
Introduction
Epidemiological studies have linked variation in the circulating inactive form of vitamin D, 25-hydroxyvitamin D 3 (25D), to risk of autoimmune diseases such as multiple sclerosis, type 1 diabetes and systemic lupus erythematosus [1] [2] [3] [4] [5] [6] [7] , consistent with the known effects of vitamin D as an immune system modulator [8] [9] [10] [11] [12] . Furthermore, genetic variation in the vitamin D pathway is linked to autoimmune disease risk. For example, several studies have highlighted associations between variants in CYP27B1, which encodes the enzyme that activates 25D to 1,25-dihydroxyvitamin D 3 (1,25D), and risk for multiple sclerosis [13] [14] [15] .
The fact that immune cells express CYP27B1 indicates that active vitamin D can be produced intra-cellularly in the immune system in response to organismal demands such as infections. Immune cells also express the vitamin D receptor (VDR), which when bound by the active 1,25D, forms a heterodimer with the retinoid X receptor (RXR) and translocates to the nucleus, resulting in transcriptional regulation of vitamin D-responsive genes [8, 9, 11, 12, 16] . The genes regulated by 1,25D are involved in various pathways including metabolic regulation, antimicrobial response and inflammatory cytokine response [7, [17] [18] [19] [20] [21] [22] [23] .
Extensive inter-individual and inter-ethnic variation in the circulating levels of 25D levels has been reported, with lower levels on average in African Americans compared to European Americans [24] [25] [26] [27] . These differences are known to be influenced by various factors such as sun exposure, dietary intake, as well as genetic variations in critical genes in the vitamin D metabolic pathway [14, 28, 29] . Despite the strong epidemiological associations of 25D levels and disease risk, randomized clinical trials aimed at testing the efficacy of vitamin D supplementation as a therapeutic intervention [4, 17, [30] [31] [32] [33] [34] have yielded mixed results [35, 36] . In addition to environmental confounders, these results could be due to inter-individual differences in the response to vitamin D, irrespective of its concentration in circulation or within the cells at the level of the target organ. Indeed, at least one study identified a polymorphism in the VDR gene that influenced the response to vitamin D supplementation [37] . However, beyond the VDR gene, little-if anything-is known about the contribution of genetics to the inter-individual variation in response to vitamin D.
The aim of this study was to map the genetic bases of inter-individual variation in the transcriptional response to 1,25D and in the inhibition of cell proliferation induced by 1,25D in primary peripheral blood mononuclear cells (PBMCs) obtained from African-American healthy individuals. We primarily focused on African-American individuals as epidemiological data indicate that they have a higher proportion of 25D deficiency, and should hence be considered prime targets of supplementation studies, which in turn could benefit from knowledge of genetic variation affecting response to supplementation. Moreover, measuring the proportion of genomewide African ancestry enabled us to test the relationship between African ancestry proportions and response to 1,25D within the same ethnic group. To isolate the effects of genetic variation on the response to active vitamin D rather than on its concentration, we treated PBMCs cultured in vitro with a fixed amount of 1,25D and, in parallel, with a vehicle control. This allowed us to characterize the response to vitamin D both at the cellular and transcriptional level and to identify genetic variants associated with cellular and transcriptional response to 1,25D. Moreover, by measuring the proportion of African ancestry in the African-American cohort in this study, we were able to directly test the relationship between African ancestry and response to 1,25D. transcriptional response [38] . All subjects were healthy donors and were not on any medication. All donors to Research Blood Components are required to sign an Institutional Review Board (IRB)-approved consent form giving permission to collect blood, and use it for research purposes. The IRB at the University of Chicago determined that this study is not human subjects research because blood samples were not shipped with individually identifiable information. Self-reported ethnicity, age, gender, date, and time of blood drawing were recorded for each donor (S1 Table) . Samples were processed in multiple successive batches. Batch number was recorded and used as a covariate.
Methods

Samples
Cell Culture and Treatment
The experimental design is illustrated in S1 Fig. We isolated peripheral blood mononuclear cells (PBMCs) from heparin-treated whole blood by density gradient centrifugation using Ficoll-Paque PLUS medium (GE Healthcare Life Sciences, Pittsburgh, PA), within 24 hours of blood draw for all the samples. PBMCs were washed in PBS and transferred to RPMI supplemented with 10% charcoal-stripped fetal bovine serum. Each sample was then divided into one aliquot of 1.8 x 10 6 cells for measuring cell proliferation, and one aliquot of 9 x 10 6 cells for genome-wide transcriptional profiling. For the cell proliferation measurements, PBMCs were cultured at 2 x 10 5 cells per well in 10% charcoal-stripped media in 96-well plates. Each donor was treated in triplicate with phytohemagglutinin (PHA) (2.5ug/ml) and either vehicle (EtOH) or 1,25-dihydroxyvitamin D3 (1,25D) (100nM) for 48 hours [38, 39] . For transcriptional profile measurements, PBMCs from each donor were cultured at 10 6 cells per well in 10% charcoal-stripped media in 24-well plates. As with the cellular proliferation measurements, each donor was treated in triplicate with PHA (2.5ug/ml) and either vehicle or 1,25D (100nM) for 6 hours. Since the mechanism of action of 1,25D is primarily transcriptional, the effects of 1,25D on cell proliferation are expected to be downstream to the transcriptional effects, hence, we chose a shorter time for the transcriptional response compared to the longer time point for cell proliferation. In addition, a strong transcriptional response to 1,25D in PBMCs had been observed at a similar time point in a previous study from our group; none of the subjects from the previous study were included here [39] . Cell type composition of the PBMCs was measured using flow cytometry as previously reported for these samples [38] , where proportions of T cells including T helper cells (CD4 + ) and cytotoxic T (CD8 + ) cells, B cells, monocytes and neutrophils were measured using antibodies specifically targeting these cell types. The cell type composition and other sample characteristics are summarized in S1 Table.
Cellular Proliferation Measurements
After 48 hours of treatment, cell proliferation was measured by H 3 -thymidine incorporation using standard protocols as previously described [38] [39] [40] . Briefly, proliferation measurements, obtained from the counts per minute (CPM) values of the thymidine incorporation assay, were obtained for each treatment (1, 25D+PHA or vehicle+PHA [41] in R, as previously described [40] . Briefly, we annotated probes by mapping their sequence to RefSeq (GRCh37) transcripts using BLAT. We discarded probes that mapped to multiple genes, or contained one or more HapMap SNPs. We applied variance stabilization transformation to all arrays, discarded poor quality probes, and quantile normalized the arrays using the default method implemented in the lumiN function. After these filters, probes mapping to 11,897 genes were used in downstream analyses. The normalized gene expression values are available in S3 Table. We used a paired t-test to identify genes that were differentially expressed between 1,25D-and vehicle-treated samples. The results from the paired t-test analysis for all 11,897 genes are available in S3 Table. False-discovery rates (FDR) were estimated using the q value function in R [42] . Gene set enrichment analysis was performed using the commercially available software Ingenuity Pathway Analysis (IPA).
Genome-Wide Association of Inhibition of Cellular Proliferation by 1,25D (I max )
Samples were genotyped on two Illumina Omni BeadChip platforms, with a total of 884,015 SNPs across the genome genotyped for each donor, as previously described [38] . We then imputed genotypes at all SNPs identified in the 1000 Genomes Project [43] using IMPUTE2 [44] , applying the output file flag option "-pgs_miss", which replaces the missing genotypes at typed SNPs with imputed genotypes. We filtered SNPs for minor allele frequency (>0.1), imputation quality (>0.9), and departure from Hardy Weinberg equilibrium (p> 0.001), resulting in a total of 4,047,158 SNPs available for all 88 samples. We performed a genome-wide association scan (GWAS) of the cellular inhibition of proliferation by 1,25D (I max ) using a likelihood ratio test correcting for genome-wide proportions of African ancestry to control for spurious associations due to population structure. Genome-wide African ancestry proportions in each donor were estimated using STRUCTURE which uses multi-locus genotype data to investigate the genetic structure of populations [45] . Prior to the GWAS analysis, I max was corrected for all covariates including age, gender, and cell type proportions.
Mapping Variation in Transcriptional Response
We performed a genome-wide test for association between log 2 fold change at every gene and SNPs within 100kb of the transcriptional start site of each gene. Transcriptional response profile data was not collected for 3 out of the 88 donors. For the 85 donors, the total number of genome-wide SNPs available for eQTL mapping that passed the filters described earlier was 4,100,242. eQTL mapping was performed using Matrix eQTL software, which performs a linear regression test for association between each SNP and each transcript, modeling the additive linear genotype effect on transcriptional response [46] . FDRs were calculated according to the Benjamini and Hochberg method [47] . We also corrected for genome-wide African ancestry proportions in this analysis.
As a complementary approach, we applied a Bayesian statistical framework that identifies different genotype-treatment interaction patterns, using the statistical software BRIdGE [48] . We mapped interaction eQTLs within 100kb of expressed genes, modeling four conditions through which SNPs could interact with transcriptional response phenotype under the two treatment conditions (1,25D and control): (i) Control-only model, where genotype is associated with transcript levels in control-treated aliquots, but not in 1,25D-treated aliquots, (ii) 1,25D-only model, where genotype is associated with transcript levels in 1,25D-treated aliquots, but not in EtOH-treated aliquots, (iii) General interaction model, where genotype is associated with transcript levels in both conditions, but with different effects in each condition, and (iv) No interaction model, where genotype is associated with transcript levels in both conditions, with equal effect in each condition (baseline eQTLs). Using a hierarchical model, information across SNPs in each gene region and across genes was combined, and a posterior probability for each gene that it follows each of the models, and that it is affected by a SNP that follows that model, was calculated.
Identifying eQTLs within Regulatory Regions
We reanalyzed published data sets of VDR ChIP-seq obtained in THP-1 monocytic cell lines treated with 1,25D and LPS or 1,25D alone [49] , and FAIRE-seq performed in THP-1 cells treated with 1,25D [50] . First, we aligned sequence reads to the human reference (GRCh37) using BWA backtrack 0.7.5. Second, we kept only sequence reads with phred-scaled mapping quality ! 30 using samtools v1.1 [51] . Third, PCR duplicate were removed with picard tool v 1.130 (http://broadinstitute.github.io/picard/). For the ChIP-seq data sets, we confirmed the quality of data sets by strand cross-correlation (SCC) analysis [52] implemented in the R script "run_spp_nodups.R" packaged in phantompeakqualtools (https://code.google.com/p/ phantompeakqualtools/). Statistically significant peaks were identified using MACS version 2 [53] with the following essential command line arguments: macs2 callpeak-bw X -g hs-qvalue = 0.05 -m 5 50, where X is a length of the bandwidth that was defined as a fragment length calculated by SCC for the ChIP-seq data or as 200 bp for the FAIRE-seq data reported in Seuter et al. (2012) .
Out of the 4,100,242 SNPs available for eQTL mapping, we identified subsets of these SNPs that were within ChIP-seq and FAIRE-seq peaks. We then used these subsets of SNPs to map response eQTLs using Matrix eQTL as described in the previous section.
Overlap between Cellular and Transcriptional Response Phenotypes
To identify genes whose transcriptional response to 1,25D may play a role in the inhibition of cell proliferation, we performed linear regression to test the association across individuals between the cellular response phenotype (I max ), and log-fold change response (1,25D-treated over vehicle-treated expression), and we estimated FDR using the q value function in R. We also applied a Bayesian method with the program Sherlock [54] to predict putative causal genes associated with I max . This method predicts causal genes by identifying SNPs in these genes that are associated both with gene expression in cis and trans, and with the trait of interest, in our case, I max . We used the results from the response cis-eQTL mapping and the GWAS of I max to perform this analysis, setting the prior for association of each SNP with gene expression in cis, as well as association of each SNP with I max , to 0.01. We chose this high prior due to the fact that we were examining transcriptional and cellular response phenotypes in primary cells obtained from the same individuals. The statistical significance of the Bayes factor for each gene was indicated by the corresponding p-values, which were calculated by permutation of the GWAS data, as detailed by He et al. (2013) .
Results
Mapping Variation in Inhibition of Cellular Proliferation by 1,25D
To characterize inter-individual variation in cellular response to 1,25D, we measured cellular proliferation in PBMCs, which had been stimulated for 48 hours with PHA in the presence of either 1,25D or its vehicle (EtOH) as a control. I max was calculated as the proportion of proliferation in 1,25D treated cells relative to proliferation in vehicle-treated cells. The average I max value across the 88 samples was 25%, with a maximum I max of 80%. Negative I max values were observed in some samples, where there was more proliferation after 1,25D treatment (S2 Table  and S3 Fig) .
Using a simple linear regression, we measured the association between each donor's age, gender, time of collection, batch, serum 25D and cortisol levels, and found no significant correlations between these covariates and I max . We also found no significant correlations between cell type proportions, as well as baseline levels of the vitamin D receptor gene (VDR), and I max (S4 Table) . However, to avoid any potential sources of confounding, we corrected I max for all of these covariates before further downstream analyses.
To control for spurious associations potentially caused by population structure, we corrected for the proportion of genome-wide African ancestry in each donor, estimated using the program STRUCTURE. The median proportion of African ancestry in our donors was 81.4%, with an interquartile range of 14.7%. There were no significant correlations between I max , or the other covariates, and proportion of African ancestry. However, there was a negative correlation between the genome-wide proportion of African ancestry and serum 25D levels (p = 0.035, β = -0.034) (S2 Fig), which suggests a genetic contribution to the higher prevalence of vitamin D insufficiency observed in African Americans [24] . The average serum 25D level in our African American donors was 20.81nM with a standard deviation of 10.39nM, which is a level considered to be at risk for deficiency according to the Institute of Medicine definitions (less than 30nM) [55] .
To investigate the genetic bases of variation in I max , we carried out a genome-wide association scan for a total of 4,047,158 SNPs and identified genome-wide significant SNPs in chromosomes 5 and 18 ( Fig 1A and 1B) . The top signal of association was an intergenic SNP in chromosome 18 (rs1893662, p = 2.32 x 10 −8 ) (Fig 1A and 1C , S5 Table) . The A allele was associated with increased inhibition of proliferation ( Fig 1E) , and had a lower frequency in populations of African ancestry compared to European and Asian populations (allele frequency: 0.325, 0.811, and 0.648 respectively) (S4A Fig). The next strongest signal of association was an intergenic SNP in chromosome 5 (rs6451692, p = 2.55 x 10 −8 ) (Fig 1A and 1D , S5 Table) . The C allele was associated with increased inhibition of proliferation (Fig 1F) , and had a higher frequency in populations of African ancestry compared to European and Asian populations (allele frequency: 0.839, 0.565, and 0.198 respectively) (S4B Fig). The closest gene to this SNP is CCL28, which encodes a chemokine that recruits T cells, eosinophils, and B cells to mucosal sites; other genes within 100 kb of this SNP are two uncharacterized open reading frames (C5orf28 and C5orf35) and PAIP1, which plays a role in stimulating translation initiation. Interestingly, we observed a marginal association between rs6451692 C allele and transcriptional response of PAIP1 to 1,25D (p = 0.02, beta = -0.39) (S6 Table) . In addition, this SNP lies less than 1 kb away from H3K4me1 enhancer-associated chromatin marks, DNase I hypersensitive sites and binding events for transcription factors such as TCF7L2, GATA3 and CEBPB in seven cell lines from the ENCODE project, including lymphoblastoid cell lines [56] 
(S5 Fig).
These chromatin marks highlight the potential regulatory activity of rs6451692 on transcriptional activity in immune cells.
To determine the proportion of variation of I max explained by the top two SNPs in chromosomes 18 and 5, we examined the correlation coefficient from the linear model measuring the association between the top two associated SNPs and I max . These two SNPs had a large effect on I max , where rs1893662 explained 29.94% of the phenotypic variation in our samples, while rs6451692 explained 29.8% of the phenotypic variation in our samples. These top two SNPs explained~45% of the variation in I max .
Mapping Variation in Transcriptional Response to 1,25D
We measured the expression of 11,897 genes in PBMCs from 85 donors treated with 100nM 1,25D and vehicle for 6 hours. We identified 720 genes differentially expressed (DE) in response to 1,25D at a FDR<0. , FDR = 6.5 x 10 −2 ) (S7 Table) , confirming the important role of 1,25D as an immunomodulator. In addition, there was an enrichment of the VDR/RXR activation pathway (p = 7.0 x 10
, FDR = 6.5 x 10
), including genes such as CD14, which encodes a monocyte surface antigen mediating innate immune response to bacterial lipopolysaccharide (LPS), CAMP which encodes an antimicrobial peptide, and CYP24A1 which encodes the enzyme that initiates the degradation of 1,25D. A previous study characterizing patterns of transcriptional response to 1,25D and LPS in primary monocytes also found an overlapping list of immune response pathways identified in this study enriched among genes that were significantly down-regulated by 1,25D [57] .
In order to identify polymorphisms that influence the transcriptional response to 1,25D, we tested the association between log 2 fold change in transcript levels at each expressed gene and SNPs within 100kb of each gene using Matrix eQTL. Because DE genes tend to be those with consistent differences in transcript levels across all individuals, they may be biased against genes with common regulatory polymorphisms. For this reason, we did not limit our mapping analyses to the DE genes. We identified response cis-eQTLs for 8 genes at a FDR<0.10, with the most significant response eQTLs including the transcriptional factor ets variant 3-line (ETV3L), and EH-domain containing 4 (EHD4), which plays a role in early endosomal transport (Table 1A, S6 Fig) . Mapping log 2 -fold change does not distinguish among the types of genotype-by-treatment interactions that influence transcriptional response. To do that, we applied a Bayesian statistical framework using the BRIdGE software, which compares different interaction models to each other and to a null model of no genotypic effect in both treatment conditions. We identified 4 genes with high confidence interactions (posterior probability of interaction > 0.7) between 1,25D treatment and SNP genotype; all these interaction eQTLs followed a 1,25D-only model, namely genotype has an effect on transcript levels in the 1,25D-treated aliquot but not in the control-treated one (Table 1B) . These interaction eQTLs included the top 2 most significant response eQTLs that had been identified by mapping log 2 fold change: ETV3L and EHD4. In addition, we identified interaction eQTLs in leucine rich repeat containing 25 (LRRC25), which is involved in activation of various immune cell types, and the transcriptional regulator unkempt family zinc finger (UNK).
To evaluate additional response cis-eQTLs found in VDR response elements, we identified 988 SNPs within VDR ChIP-seq peaks from a dataset of published THP-1 monocytic cell lines treated with 1,25D [49] , and mapped response eQTLs using this subset of SNPs. At a distance of 1Mb, we identified statistically significant response eQTLs (FDR < 0.10) in two genes: FERM Domain Containing 6 (FRMD6), a key activator of the Hippo kinase pathway with important roles in regulating cell proliferation and apoptosis [58] , and the undefined KIAA1211 (Fig 2) . In addition, we identified 17,417 SNPs within open chromatin regions, identified by FAIRE-seq from a published dataset of THP-1 monocytic cell lines treated with 1,25D [50] . Within this subset, we identified statistically significant response eQTLs (FDR < 0.10) in ETV3L, EHD4 and ZNHIT1 (S8 Table) . These eQTLs were in strong linkage disequilibrium (LD) with the response eQTLs we had identified for the same genes (r 2 = 0.93, 0.69 and 0.95 for ETV3L, EHD4 and ZNHIT1, respectively), raising the possibility that these response eQTLs are due to variants affecting open chromatin conformation.
Combined Analysis of Cellular and Transcriptional Response Phenotypes
We examined the relationship between the two 1,25D response phenotypes: transcriptional response and the inhibition of cellular proliferation. To evaluate whether the SNPs associated with inhibition of cellular proliferation exerted their effects through regulation of transcriptional response, we first examined associations between the two most significant I max GWAS SNPs and log 2 fold change expression at all 11,897 genes expressed in the PBMCs. At a FDR < 0.10, we found no statistically significant associations. We then focused on the subset of genes where log 2 fold change in expression was associated with I max , reasoning that these genes are more likely to share genetic variation influencing both transcriptional response and inhibition of cell proliferation. Using a linear regression approach, we identified 16 associated genes at an FDR < 0.2 (S9 Table) . When we considered only these genes, we found significant associations between two I max -associated genes (PCSK6 and RASL11A) and the top GWAS SNP in chromosome 18, rs1893662, and one I max -associated gene (KNCN) with the second GWAS SNP in chromosome 5, rs6451692 ( Table 2) , at a Bonferroni-corrected p < 3.125 x 10 −3
. Both PCSK6 and KNCN are involved in vesicular trafficking and secretory pathways, highlighting potential molecular mechanisms involved in inhibition of proliferation by vitamin D.
We further predicted putative causal genes associated with I max based on a Bayesian approach implemented in the program, Sherlock, using our response eQTL and GWAS of I max data. At p < 10 −4 (FDR = 0.3), we identified three putative I max -associated genes, including the translation initiation gene PAIP1, a transcriptional repressor gene ZNF649, and a golgin family gene GORAB (S10 Table) . Interestingly, the top I max -associated SNP in chromosome 5, rs6451692, was identified as being associated with transcriptional response of PAIP1 using this method, which suggests that this SNP influences the inhibition of cell proliferation through a transcriptional mechanism in PBMCs.
Discussion
While the inter-individual variation in the circulating inactive form of vitamin D, 25D, has been well documented, little is known about the inter-individual variation in immune response to the active 1,25D. In this study, we identified several variants underlying variation in response to 1,25D both at the cellular and transcriptional level using primary peripheral blood mononuclear cells from a cohort of healthy individuals of African-American ancestry. These variants highlight genes with an important role in mediating the immunomodulatory effects of 1,25D, thereby providing a genetic basis for inter-individual variation in those aspects of the immune response influenced by vitamin D. Intergenic SNPs in chromosome 5 that were significantly associated with inhibition of cellular proliferation by 1,25D are located close to several genes such as CCL28, which encodes a chemokine that recruits T cells, eosinophils, and B cells to mucosal sites [59] [60] [61] , and PAIP1 which encodes a protein that interacts with poly(A)-binding protein and with the eIF4A capbinding complex, stimulating translation initiation [62] . Interestingly, we found a marginal association between rs6451692 and down-regulation of PAIP1, raising the possibility that this polymorphism influences the inhibitory effects of 1,25D on immune cell proliferation by regulating the transcriptional response of a translation initiation gene.
We observed several regulatory marks near rs6451692 in seven cell lines from the ENCODE project, including an enrichment of H3K4me1 histone mark, which is associated with enhancers. There was also an abundance of transcription factor binding events in this region, where rs6451692 overlaps a TCF7L2 binding site. TCF7L2 is a member of the high mobility group DNA binding protein family of transcription factors which has been implicated in type 2 diabetes risk [63] [64] [65] . Other transcription factors with binding sites in the region include RXRA, which binds to the VDR, forming a heterodimer which then regulates transcription of vitamin D-responsive genes, GATA3 which has important roles in T cell development [66, 67] , and CEBPB which plays an important role in regulating immune and inflammatory response genes [68] [69] [70] [71] . The abundance of transcription factor binding events in this region suggests that the regulatory activity of rs6451692 on the surrounding genes could involve enhancer activity. Further functional validation assays specifically in PBMCs treated with vitamin D are needed to elucidate the regulatory mechanisms of this I max GWAS interval.
In addition, from the Genotype-Tissue Expression (GTEx) project catalogue [72] , we observed that rs6451692 is associated with variation in transcript levels of surrounding genes in multiple tissues. The C allele is associated with decreased expression of CCL28 in the pancreas, decreased expression of NNT in skeletal muscle, and decreased expression of the novel antisense long non-coding RNA RP11-159F24.5 in multiple tissues such as subcutaneous adipose, tibial nerve, testis, thyroid and skin, suggesting that this variant influences the regulation of several genes in that genomic region. RP11-159F24.5 was not covered by probes in our expression microarrays, therefore we cannot determine if rs6451692 has effects on the expression of this gene in PBMCs. Enrichment of immune response pathways such as TREM1 signaling, which enhances innate immune responses to microbial infections and activates pro-inflammatory responses [73] , and T helper cell differentiation among the genes that respond transcriptionally to 1,25D, underscores the important immunomodulatory role played by 1,25D [8] [9] [10] . This is consistent with results from previous studies from our group investigating the transcriptional response to 1,25D in PBMCs [39] and transcriptional response to 1,25D and bacterial lipopolysaccharide (LPS) in primary monocytes [57] . Both of these studies found an enrichment of immune response pathways, particularly among genes that were down-regulated by 1,25D. This highlights the important immunomodulatory role played by 1,25D across cells in both the innate and adaptive immune system. In addition, translation initiation pathways were significantly enriched among the genes that were up-regulated by 1,25D in monocytes in the previous study. This pathway was not significantly enriched amongst the DE genes in PBMCs in this study (S7 Table) , which could indicate that this effect is particularly strong in the innate immune cells. It was however interesting to note the marginal association between one of the top I max SNPs, rs6451692, and transcriptional response of PAIP1, a translation initiation gene.
Several studies have mapped genome-wide VDR binding sites in different immune cell lines [49, 74, 75] . Interestingly, one study examined VDR binding sites in primary CD4 + T cells from nine individuals with varying 25D levels and reported a correlation between 25D levels and number of VDR binding sites [76] , directly supporting the notion that vitamin D status affects the response to vitamin D. In addition, genome-wide maps of VDR binding sites allow identification of genetic variants within VDR binding sites that in turn may influence variation in the transcriptional response to vitamin D. Interestingly, one such study reported that many risk variants for autoimmune diseases detected in genome-wide association studies fall within VDR binding sites [70] , suggesting that disease risk is influenced not only by inter-individual variation in 25D levels, but also by variation in the response to vitamin D. To build on these studies, we focused on mapping variants that regulate genome-wide transcriptional response to 1,25D in primary PBMCs. The cis-response eQTLs identified in this study highlighted several genes that could play an important role in mediating the effects of 1,25D in the immune response. Genes identified using both the linear regression and Bayesian eQTL mapping approaches included ETV3L, which is a transcriptional regulator that has been reported to play a role in inhibiting proliferation of neural progenitor cells [77] , and EHD4, which plays a role in controlling early endosomal trafficking [78, 79] . Furthermore, we identified statistically significant response eQTLs in regions of open chromatin, marked by FAIRE-seq peaks in ETV3L, EHD4, and ZNHIT1-a gene that is implicated in regulating the transcriptional activity of the orphan nuclear receptor Rev-erbbeta [80] . Interestingly, both ETV3L and ZNHIT1 are transcriptional regulators, raising the possibility that these loci could play a role in modulating transcriptional response of other genes to 1,25D in immune cells. We then identified variants within VDR binding sites that regulate transcriptional response possibly by altering the structure or accessibility of the VDR binding site. We did this by combining our cis-response eQTL data with a published VDR ChIP-seq dataset from a monocytic cell line [49] . We identified a response eQTL within a VDR binding site in FRMD6, which is part of the conserved Hippo pathway playing a critical role in controlling organ size by regulating both cell proliferation and apoptosis [81, 82] . FRMD6 has been linked to various complex diseases such as asthma, Alzheimer's disease, and lung cancer [82] [83] [84] , where it is thought to have tumor suppressor properties. The T allele of rs3783273, which is associated with increased FRMD6 expression (Fig 2) , could alter the binding properties of the VDR to its receptor elements in FRMD6 and could affect the transcriptional response of this gene to 1,25D. Given its putative tumor suppressor properties, FRMD6 may play a crucial role in mediating the role of 1,25D in inhibiting proliferation of immune cells.
The published VDR ChIP-seq and FAIRE-seq data were collected in a monocytic cell line stimulated with LPS and treated with 1,25D. Our data, in contrast, were collected in a heterogeneous population of immune cells treated with PHA, which was shown to stimulate transcriptional responses related to both innate and adaptive immunity [38] . Therefore, the data from the monocytic cell line may miss some peaks specific to other cell types present in PBMCs, that is, primarily T cells, but it may also contribute valuable information about the regulatory architecture of 1,25D response in immune cells. Future work should incorporate VDR ChIP-seq and FAIRE-seq studies in primary immune cells under the same experimental conditions.
Using both simple linear regression analysis and a Bayesian approach, we combined the information from response cis-eQTL mapping and the GWAS of I max to identify candidate genes mediating the inhibitory effects of cellular proliferation by 1,25D. Genes such as PAIP1, ZNF649 and GORAB contained I max -associated SNPs that also regulated transcriptional response of these genes in cis. While PAIP1 encodes a protein that is involved in initiating translation, ZNF649 encodes a transcriptional repressor that inhibits transcription factor complexes such as AP-1 which is involved in cellular proliferation and survival [85] [86] [87] , and GORAB encodes a golgin family member with roles in the intracellular membrane trafficking and the secretory pathways of the Golgi apparatus [88, 89] . In addition, we identified trans effects of the top GWAS SNPs on transcriptional response of genes such as PCSK6 and KNCN, which both have roles in vesicular trafficking and secretory pathways, highlighting potential molecular mechanisms involved in the anti-proliferative activity of 1,25D. Increased PCSK6 expression has been previously implicated in risk for rheumatoid arthritis [90] . Interestingly, knockdown of PCSK6 by RNA interference significantly decreased proliferation, invasion, and migration of cultured rheumatoid arthritis synovial fibroblasts. It is plausible that the top I maxassociated SNP, rs1893662, regulates the anti-proliferative activity of 1,25D by regulating PCSK6 transcription in immune cells. The potential mechanisms through which these putative I max -associated candidate genes could mediate the inhibition of proliferation of immune cells by 1,25D should be further studied.
In summary, mapping response to 1,25D at both the cellular and transcriptional level in immune cells enabled identification of variants which may influence inter-individual variation in response to 1,25D, and identification of genes with potentially crucial roles in mediating the immunomodulatory role of 1,25D. Characterizing these genetic mediators of 1,25D activity in the immune system could inform additional therapeutic targets and markers for immunerelated diseases in future randomized VD supplementation trials. Table. Genes whose transcription responses are associated with I max at a FDR<0.2.
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